Antimicrobial Effects of Anthracene and Its Derivatives against Intestinal Bacteria

The growth-inhibitory effects of anthracene were determined against intestinal bacteria, and compared with those of its derivatives for a better understanding of structure-activity relationships. The Growth inhibiting activity was shown to vary the chemical, dose, and bacterial strain tested. In tes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Applied biological chemistry 2009, 52(4), , pp.327-330
Hauptverfasser: Kim, M.G., Chonbuk National University, Jeonju, Republic of Korea, Jeong, E.Y., Chonbuk National University, Jeonju, Republic of Korea, Lee, H.S., Chonbuk National University, Jeonju, Republic of Korea
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The growth-inhibitory effects of anthracene were determined against intestinal bacteria, and compared with those of its derivatives for a better understanding of structure-activity relationships. The Growth inhibiting activity was shown to vary the chemical, dose, and bacterial strain tested. In tests with Clostridium perfringens, anthracence evidenced strong (+++) and moderate (++) growth inhibition at 1.0 and 0.25 mg/disc, respectively, but exhibited no growth inhibition effects against lactic-acid producing bacteria and E. coli. In our study of structure-activity relationships, anthracene-9-carboxylic acid evidenced strong (+++) and moderate (++) growth inhibition at 1.0 and 0.25 mg/disc, respectively, but anthracence-9-carboxaldehyde, anthrone, and 9-(hydroxymethyl)-anthracene exhibited no growth-inhibitory effects against six intestinal bacteria. In conclusion, the growth-inhibitory activities of anthracene and anthracene-9-carboxylic acid against C. perfringens may be indicative of at least one of these pharmacological actions. Furthermore, anthracene and anthracene-9-carboxylic acid may prove useful as prospective therapeutics for the treatment of gastrointestinal diseases caused by C. perfringens.
ISSN:1738-2203
2468-0834
2234-344X
2468-0842
DOI:10.3839/jksabc.2009.058